Jpmorgan Chase & CO Precigen, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Precigen, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,078,789 shares of PGEN stock, worth $873,819. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,078,789
Previous 1,294,704
16.68%
Holding current value
$873,819
Previous $1.88 Million
9.22%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding PGEN
# of Institutions
140Shares Held
145MCall Options Held
292KPut Options Held
53.8K-
Third Security, LLC83.5MShares$67.6 Million73.5% of portfolio
-
Patient Capital Management, LLC Baltimore, MD18.2MShares$14.7 Million1.57% of portfolio
-
Black Rock Inc. New York, NY10.2MShares$8.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.76MShares$5.48 Million0.0% of portfolio
-
Iridian Asset Management LLC3.78MShares$3.06 Million0.8% of portfolio
About PRECIGEN, INC.
- Ticker PGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 208,150,000
- Market Cap $169M
- Description
- Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...